{"product_id":"bispecific-antibodies-and-car-t-cell-therapy-in-multiple-myeloma-a-patients-guide-to-new-immunotherapy-approaches","title":"Bispecific Antibodies and CAR-T Cell Therapy in Multiple Myeloma: A Patient's Guide to New Immunotherapy Approaches","description":"\u003ch1\u003eBispecific Antibodies and CAR-T Cell Therapy in Multiple Myeloma: A Patient's Guide to New Immunotherapy Approaches\u003c\/h1\u003e\n\n\u003cp\u003eMultiple myeloma (MM) remains an incurable blood cancer, but two groundbreaking immunotherapy strategies—bispecific antibodies and CAR-T cell therapy—are transforming treatment options, especially for patients whose disease has stopped responding to standard therapies. This medical review covers the approved drugs Talquetamab, Teclistamab, Elranatamab, and the CAR-T therapies idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (Cilta-cel), reporting overall response rates ranging from 61% to 97% across key clinical trials. Notably, 89% of patients successfully used Talquetamab as a \"bridge\" to CAR-T therapy, and studies show that age alone should not disqualify older patients from receiving these powerful treatments.\u003c\/p\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhat Is Multiple Myeloma and Why Is It So Difficult to Treat?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#problem\"\u003eThe Unmet Need: Relapsed\/Refractory Multiple Myeloma\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#bispecifics\"\u003eHow Bispecific Antibodies Work\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#talquetamab\"\u003eTalquetamab (Talq): Targeting a New Marker on Myeloma Cells\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#bridge\"\u003eTalquetamab as a \"Bridge\" to CAR-T Therapy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#teclistamab\"\u003eTeclistamab: The First BCMA-Targeting Bispecific\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#outpatient\"\u003eCan Teclistamab Be Given in the Outpatient Setting?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#age\"\u003eShould Age Prevent Teclistamab Treatment?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#elranatamab\"\u003eElranatamab: A Humanized Bispecific Antibody\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#emerging\"\u003eEmerging Agents: Linvoseltamab\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cart\"\u003eCAR-T Cell Therapy: A Personalized Cellular Treatment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#idecel\"\u003eIdecabtagene Vicleucel (Ide-cel)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ciltacel\"\u003eCiltacabtagene Autoleucel (Cilta-cel)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#comparison\"\u003eCilta-cel vs. Ide-cel: Efficacy Versus Toxicity\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of This Review\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a 134-patient study, 89% successfully used Talquetamab as a bridge to CAR-T therapy.\u003c\/li\u003e\n\u003cli\u003eOlder patients over 75 responded well to Teclistamab, with no grade 4 toxicity.\u003c\/li\u003e\n\u003cli\u003eOutpatient Teclistamab step-up dosing was feasible; CRS-related hospital stays averaged 2 days.\u003c\/li\u003e\n\u003cli\u003eCilta-cel showed higher response rates than Ide-cel but with more severe toxicity.\u003c\/li\u003e\n\u003cli\u003eElranatamab produced a 61% response rate with no severe cytokine release syndrome.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhat Is Multiple Myeloma and Why Is It So Difficult to Treat?\u003c\/h2\u003e\n\n\u003cp\u003eMultiple myeloma is the \u003cstrong\u003esecond most common blood cancer (hematologic cancer) in adults\u003c\/strong\u003e, and its incidence has been rising in recent years. According to the SEER database, \u003cstrong\u003e47,966 new cases\u003c\/strong\u003e were diagnosed between 2014 and 2018 in the United States alone.\u003c\/p\u003e\n\n\u003cp\u003eThe disease begins when plasma cells—a type of white blood cell responsible for producing antibodies—become malignant and multiply uncontrollably in the bone marrow. Over time, these cancer cells accumulate genetic changes: copy number modifications, secondary mutations, and epigenetic alterations. These changes create what doctors call \u003cstrong\u003eintratumor heterogeneity\u003c\/strong\u003e, meaning that within a single patient, multiple distinct clones of cancer cells exist, each with its own resistance mechanisms. This is a major reason why multiple myeloma has been so hard to cure.\u003c\/p\u003e\n\n\u003cp\u003eStandard treatments have improved survival significantly. \u003cstrong\u003eProteasome inhibitors (PIs)\u003c\/strong\u003e, \u003cstrong\u003eanti-CD38 monoclonal antibodies\u003c\/strong\u003e, and \u003cstrong\u003eimmunomodulatory drugs (IMiDs)\u003c\/strong\u003e are now used in various combinations. Patients who are eligible for autologous stem cell transplantation (ASCT)—a procedure that uses the patient's own stem cells—or CAR-T cell therapy often receive these combination treatments for three to six months as a \"bridge\" to prepare their bodies for the more intensive procedure.\u003c\/p\u003e\n\n\u003ch2 id=\"problem\"\u003eThe Unmet Need: Relapsed\/Refractory Multiple Myeloma\u003c\/h2\u003e\n\n\u003cp\u003eDespite these advances, some patients become refractory, meaning their disease stops responding to treatment. This is especially challenging for patients who have been exposed to all three major drug classes: anti-CD38 antibodies, proteasome inhibitors, and immunomodulatory drugs. These \u003cstrong\u003e\"triple class exposed\" patients\u003c\/strong\u003e face particularly poor outcomes. According to the LocoMMotion study, patients with relapsed\/refractory multiple myeloma (RRMM) receiving standard-of-care therapy had only a \u003cstrong\u003e29.8% overall response rate\u003c\/strong\u003e and a \u003cstrong\u003emedian overall survival of just 12.4 months\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eFortunately, the treatment landscape is now being reshaped by two powerful immunotherapy approaches: \u003cstrong\u003ebispecific antibodies\u003c\/strong\u003e that redirect the body's own T cells to attack myeloma cells, and \u003cstrong\u003eCAR-T cell therapy\u003c\/strong\u003e, which involves genetically engineering a patient's T cells to recognize and destroy cancer cells. This review explores both strategies in depth and provides practical guidance on how they are being sequenced and administered in real-world clinical practice.\u003c\/p\u003e\n\n\u003ch2 id=\"bispecifics\"\u003eHow Bispecific Antibodies Work\u003c\/h2\u003e\n\n\u003cp\u003eBispecific antibodies are engineered proteins that act as a bridge between two different targets. One end of the antibody binds to a protein on the surface of the patient's immune T cells (usually \u003cstrong\u003eCD3\u003c\/strong\u003e), while the other end binds to a protein on the surface of myeloma cells. This physical connection forces the T cell to engage with and kill the myeloma cell.\u003c\/p\u003e\n\n\u003cp\u003eThere are three key target proteins on myeloma cells that bispecific antibodies are designed to recognize:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBCMA (B-cell maturation antigen):\u003c\/strong\u003e A cell membrane receptor glycoprotein found almost exclusively on plasma blasts and plasma cells, making it an ideal therapeutic target. Its N-terminal section contains six motifs, classifying it as part of the tumor necrosis factor receptor superfamily 17 (TNFRSF17)\/CD269. BCMA plays a vital role in immune function.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGPRC5D (G-protein-coupled receptor family C group 5 member D):\u003c\/strong\u003e A type C seven-pass transmembrane receptor protein that is expressed at levels \u003cstrong\u003eat least 500-fold higher\u003c\/strong\u003e on malignant and normal plasma cells in the bone marrow compared to circulating plasma cells. Among normal tissues, only hair follicles express GPRC5D.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFcRH5 (Fc receptor-homolog 5):\u003c\/strong\u003e Another emerging target on myeloma cells.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese bispecific agents have been proven to induce deep and durable responses in heavily pre-treated patients, offering new hope where older treatments have failed.\u003c\/p\u003e\n\n\u003ch2 id=\"talquetamab\"\u003eTalquetamab (Talq): Targeting a New Marker on Myeloma Cells\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eTalquetamab (Talq)\u003c\/strong\u003e is a bispecific antibody directed against GPRC5D. It has been approved for patients with relapsed\/refractory multiple myeloma who have progressed on \u003cstrong\u003eat least four prior lines of therapy\u003c\/strong\u003e. Its approval was based on the pivotal \u003cstrong\u003eMonumenTAL-1 trial\u003c\/strong\u003e, which demonstrated:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA \u003cstrong\u003e70% overall response rate (ORR)\u003c\/strong\u003e—meaning 7 out of 10 patients experienced significant tumor shrinkage\u003c\/li\u003e\n  \u003cli\u003eA \u003cstrong\u003emedian duration of response (DOR) of 10.2 months\u003c\/strong\u003e, showing that responses were meaningful and lasted nearly a year\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHowever, Talquetamab has a distinctive side effect profile due to GPRC5D expression on hair follicles. Patients commonly experience:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDysgeusia (taste changes): 60%\u003c\/strong\u003e of patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeight loss: 30%\u003c\/strong\u003e of patients\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSkin changes: 70%\u003c\/strong\u003e of patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTable 1 below summarizes the approved bispecific antibodies covered in this review, with their targets, trial names, response rates, and notable toxicities:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTable 1. Currently Approved Bispecific Antibodies with Trial Data\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTalquetamab\u003c\/strong\u003e (Target: GPRC5D; Pivotal trial: MonumenTAL-1): ORR 70%, median DOR 10.2 months. Notable toxicities: cytokine release syndrome (CRS) in 78%, dysgeusia, skin\/nail changes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTeclistamab\u003c\/strong\u003e (Target: BCMA; Pivotal trial: MajesTEC-1): ORR 63%, median DOR 18.4 months. Notable toxicities: CRS in 72%, neurotoxicity, infections.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eElranatamab\u003c\/strong\u003e (Target: BCMA; Pivotal trial: MagnetisMM-3): ORR 61%, median DOR not reached by 14 months of follow-up. Notable toxicities: CRS in 58%, cytopenias, infections.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLinvoseltamab\u003c\/strong\u003e (Target: BCMA; Pivotal trial: LINKER-MM1): ORR 71%, median DOR data maturing. Notable toxicities: CRS, cytopenias, infections.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"bridge\"\u003eTalquetamab as a \"Bridge\" to CAR-T Therapy\u003c\/h2\u003e\n\n\u003cp\u003eA key question in clinical practice is how bispecific antibodies and CAR-T therapy should be sequenced. The authors of this review suggest using \u003cstrong\u003eTalquetamab as a therapeutic bridge to BCMA CAR-T therapy\u003c\/strong\u003e. The rationale is that Talquetamab can achieve significant disease debulking (reducing the tumor burden) before the patient undergoes CAR-T cell collection and infusion, and it provides an opportunity for \u003cstrong\u003edual targeting\u003c\/strong\u003e—attacking the myeloma through a different antigen (GPRC5D) than the CAR-T cells will target (BCMA).\u003c\/p\u003e\n\n\u003cp\u003eA retrospective multi-institutional study evaluated the safety and efficacy of this bridging strategy. The study included \u003cstrong\u003e134 patients\u003c\/strong\u003e, of whom:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e43%\u003c\/strong\u003e had extramedullary disease (myeloma outside the bone marrow)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e45%\u003c\/strong\u003e had high-risk cytogenetics (genetic abnormalities associated with aggressive disease)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e10%\u003c\/strong\u003e had prior BCMA therapy\u003c\/li\u003e\n  \u003cli\u003ePatients had received a \u003cstrong\u003emedian of 5 prior treatment lines\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAmong patients treated with Talquetamab as bridging therapy, \u003cstrong\u003e77% were treated every 2 weeks\u003c\/strong\u003e and \u003cstrong\u003e23% were treated every 4 weeks\u003c\/strong\u003e. Critically, \u003cstrong\u003e119 patients (89%) successfully proceeded to CAR-T cell therapy\u003c\/strong\u003e. The distribution of CAR-T therapies used included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eIdecabtagene vicleucel (Ide-cel): 18%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eCiltacabtagene autoleucel (Cilta-cel): 82%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe results were encouraging. In patients who received Talquetamab as a bridge to CAR-T:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e49%\u003c\/strong\u003e had a deep response (\u003cstrong\u003ecomplete response or stringent complete response\u003c\/strong\u003e, meaning no detectable myeloma)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e46%\u003c\/strong\u003e had unchanged response (stable disease)\u003c\/li\u003e\n  \u003cli\u003eMedian \u003cstrong\u003eprogression-free survival (PFS)\u003c\/strong\u003e was \u003cstrong\u003e13 months\u003c\/strong\u003e (interquartile range 10 to not estimable)\u003c\/li\u003e\n  \u003cli\u003eMedian follow-up from the first Talquetamab dose was \u003cstrong\u003e7.5 months\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eFollowing CAR-T, the median follow-up was \u003cstrong\u003e4.9 months\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe toxicities observed with this bridging approach are summarized in Table 2:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTable 2. Toxicities for Talquetamab and CAR-T\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCytokine release syndrome (CRS):\u003c\/strong\u003e Talquetamab 68% (grade 1–2 only; no grade ≥3 reported) vs. CAR-T 72%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eImmune effector cell-associated neurotoxicity (ICANS):\u003c\/strong\u003e Talquetamab 10% vs. CAR-T 10%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSkin toxicities:\u003c\/strong\u003e Talquetamab 42%; not reported for CAR-T\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOral toxicities:\u003c\/strong\u003e Talquetamab 56%; not reported for CAR-T\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDelayed neurotoxicity:\u003c\/strong\u003e CAR-T 1.5%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInfections:\u003c\/strong\u003e CAR-T 27%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSecondary malignancies:\u003c\/strong\u003e CAR-T 1.5%\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNew Guillain-Barré syndrome:\u003c\/strong\u003e 0% for both\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParkinsonian symptoms:\u003c\/strong\u003e 0% for both\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eUltimately, \u003cstrong\u003e85% of patients proceeded to CAR-T therapy\u003c\/strong\u003e, achieving a \u003cstrong\u003ecomplete or stringent complete response (CR\/sCR) in 52%\u003c\/strong\u003e, a \u003cstrong\u003every good partial response (VGPR) in 71%\u003c\/strong\u003e, and an \u003cstrong\u003eoverall response rate (ORR) of 95%\u003c\/strong\u003e, with most patients deepening their response over time. In plain terms, this means that more than 9 out of every 10 patients who followed this sequential approach experienced significant benefit, and more than half achieved what appears to be complete elimination of detectable disease.\u003c\/p\u003e\n\n\u003ch2 id=\"teclistamab\"\u003eTeclistamab: The First BCMA-Targeting Bispecific\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eTeclistamab\u003c\/strong\u003e is the first bispecific antibody designed to redirect T cells by binding to CD3 on T-lymphocytes and BCMA on myeloma cells. It uses a \u003cstrong\u003eweight-based dosing system\u003c\/strong\u003e that delivers sustained, significant responses in patients with relapsed\/refractory multiple myeloma. The \u003cstrong\u003eMajesTEC-1 trial\u003c\/strong\u003e reported a \u003cstrong\u003e63% overall response rate\u003c\/strong\u003e and an \u003cstrong\u003e18.4-month median duration of response\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eBecause of the risk of toxicities—particularly cytokine release syndrome—and the need for close monitoring, step-up dosing of Teclistamab is commonly done in the \u003cstrong\u003einpatient (hospital) setting\u003c\/strong\u003e. However, the authors examined whether this could be done safely in the outpatient (clinic) setting, which would be far more convenient for patients.\u003c\/p\u003e\n\n\u003ch2 id=\"outpatient\"\u003eCan Teclistamab Be Given in the Outpatient Setting?\u003c\/h2\u003e\n\n\u003cp\u003eA retrospective study evaluated successful outpatient dose escalation (step-up dosing, or SUD) of Teclistamab from 2022 to 2023. The study included \u003cstrong\u003e57 patients, of whom 89.2% (n=57)\u003c\/strong\u003e initiated Teclistamab in the outpatient setting. Key findings included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e54.2%\u003c\/strong\u003e of patients completed step-up dosing using the \u003cstrong\u003e3-day dose interval\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e18 patients (31.6%)\u003c\/strong\u003e developed cytokine release syndrome \u003cstrong\u003eincluding one patient with Grade 4 CRS\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eAll patients who developed CRS required hospital admission\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTocilizumab\u003c\/strong\u003e (a medication used to treat CRS) was required in \u003cstrong\u003e6 patients\u003c\/strong\u003e, but it was not given prophylactically\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003emedian CRS-related hospital stay was just 2 days\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors note that these rates of CRS and healthcare utilization burden were low—actually lower than those reported in the pivotal MajesTEC-1 trial. However, they caution that this may be partly due to underreporting in the outpatient setting and the limitations of retrospective data review. Overall, the conclusion was that \u003cstrong\u003eoutpatient administration of Teclistamab appears feasible\u003c\/strong\u003e, offering patients a more convenient treatment option without compromising safety.\u003c\/p\u003e\n\n\u003ch2 id=\"age\"\u003eShould Age Prevent Teclistamab Treatment?\u003c\/h2\u003e\n\n\u003cp\u003eBecause older patients are often excluded from clinical trials, there is uncertainty about whether they benefit equally from new treatments. A retrospective multicenter study specifically addressed this question by comparing two cohorts of patients with RRMM: those \u003cstrong\u003eyounger than 75 years\u003c\/strong\u003e and those \u003cstrong\u003eolder than 75 years\u003c\/strong\u003e, all of whom received standard-of-care Teclistamab. The study included \u003cstrong\u003e83 patients in the older cohort\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eKey efficacy results:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe older group had a \u003cstrong\u003elower rate of high-risk cytogenetics (45%)\u003c\/strong\u003e compared to the younger group (\u003cstrong\u003e58%\u003c\/strong\u003e)\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eoverall response rate was 62% in the older group\u003c\/strong\u003e versus \u003cstrong\u003e53% in the younger group\u003c\/strong\u003e—meaning older patients actually responded better\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eKey safety results:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eICANS:\u003c\/strong\u003e 19% in older group vs. 13% in younger group (not statistically significant)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCRS:\u003c\/strong\u003e 59% in older group vs. 52% in younger group (not statistically significant)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo grade 4 events\u003c\/strong\u003e were observed in the older group\u003c\/li\u003e\n  \u003cli\u003eTime to CRS onset and maximum CRS severity did not differ significantly between age groups\u003c\/li\u003e\n  \u003cli\u003eTime to ICANS onset was shorter in the older group (\u003cstrong\u003e3 days\u003c\/strong\u003e) compared to the younger group (\u003cstrong\u003e4 days\u003c\/strong\u003e), but this difference was not statistically significant\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInfection rate was higher in the older group: 25%\u003c\/strong\u003e versus \u003cstrong\u003e10%\u003c\/strong\u003e in the younger group\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese real-world results mirror those seen in the MajesTEC-1 trial's elderly subgroup, showing good efficacy without substantially increased toxicity in older patients. Based on these findings, the authors explicitly recommend that \u003cstrong\u003eage should not preclude the use of Teclistamab treatment\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"elranatamab\"\u003eElranatamab: A Humanized Bispecific Antibody\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eElranatamab (PF-06863135)\u003c\/strong\u003e is a humanized bispecific antibody designed to target myeloma cells by simultaneously binding both CD3 receptors on T cells and BCMA on myeloma cells. Once bound, T cells are activated to induce a cytotoxic (cell-killing) T-cell response against the myeloma.\u003c\/p\u003e\n\n\u003cp\u003eIn the \u003cstrong\u003ephase 2 MagnetisMM-3 trial\u003c\/strong\u003e, patients with relapsed or refractory multiple myeloma received subcutaneous (under-the-skin) Elranatamab \u003cstrong\u003eonce weekly after two step-up priming doses\u003c\/strong\u003e. The trial reached its primary endpoint with impressive results:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eConfirmed objective response rate (ORR) of 61.0%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eComplete response rate of 35%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003eAmong responders, \u003cstrong\u003e80% achieved improved or sustained response for ≥6 months\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAt a \u003cstrong\u003emedian follow-up of 14.7 months\u003c\/strong\u003e, several key measures had not yet been reached, indicating lasting benefit:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMedian duration of response: \u003cstrong\u003e71.5%\u003c\/strong\u003e of patients maintaining response at that time point\u003c\/li\u003e\n  \u003cli\u003eProgression-free survival: \u003cstrong\u003e50.9%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eOverall survival: \u003cstrong\u003e56.7%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFrequently reported adverse events (any grade; grade 3–4) included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eInfections: 69.9% (any grade), 39.8% (grade 3–4)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eCytokine release syndrome: 57.7% (any grade), 0% (grade 3–4)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eAnemia: 48.8% (any grade), 37.4% (grade 3–4)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eNeutropenia (low white blood cell count): 48.8% (any grade), 48.8% (grade 3–4)\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eNotably, despite the frequent low-grade CRS, there were \u003cstrong\u003eno grade 3 or 4 CRS events\u003c\/strong\u003e with Elranatamab, which is particularly reassuring for patient safety.\u003c\/p\u003e\n\n\u003ch2 id=\"emerging\"\u003eEmerging Agents: Linvoseltamab\u003c\/h2\u003e\n\n\u003cp\u003eThe field continues to evolve rapidly. \u003cstrong\u003eLinvoseltamab\u003c\/strong\u003e is a BCMA-targeting bispecific antibody that received \u003cstrong\u003eaccelerated approval from the U.S. Food and Drug Administration (FDA) in July 2025\u003c\/strong\u003e. This approval was based on promising results from the \u003cstrong\u003eLINKER-MM1 trial\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eORR of 70.9%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKaplan-Meier estimated median DOR of 29.4 months\u003c\/strong\u003e—the longest duration of response reported among the bispecific antibodies discussed here\u003c\/li\u003e\n  \u003cli\u003eLow-grade cytokine release syndrome was reported in a minority of patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLonger-term follow-up data are still pending, which will help oncologists determine exactly how linvoseltamab fits into the treatment sequencing landscape for RRMM. As the authors note, the growing number of available agents creates both opportunities and challenges in choosing the right treatment at the right time for each patient.\u003c\/p\u003e\n\n\u003ch2 id=\"cart\"\u003eCAR-T Cell Therapy: A Personalized Cellular Treatment\u003c\/h2\u003e\n\n\u003cp\u003eCAR-T therapy is fundamentally different from bispecific antibodies. Rather than being a manufactured protein given to the patient, CAR-T therapy involves \u003cstrong\u003ecollecting the patient's own T cells, genetically engineering them in a laboratory to recognize cancer cells, multiplying them, and infusing them back into the patient\u003c\/strong\u003e. These engineered \"living drugs\" then seek out and destroy myeloma cells.\u003c\/p\u003e\n\n\u003cp\u003eThe approval history of CAR-T agents for multiple myeloma shows rapid progress:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2022:\u003c\/strong\u003e Ide-cel was approved for RRMM with progression on \u003cstrong\u003eat least four prior lines of therapy\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2022:\u003c\/strong\u003e Cilta-cel was approved for the same indication\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2024:\u003c\/strong\u003e Ide-cel's approval was \u003cstrong\u003eexpanded\u003c\/strong\u003e to include patients with progression on \u003cstrong\u003etwo prior lines of therapy\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2024:\u003c\/strong\u003e Cilta-cel was expanded to include \u003cstrong\u003elenalidomide-refractory patients\u003c\/strong\u003e with progression on \u003cstrong\u003eat least one prior line of therapy\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis expansion to earlier lines of therapy reflects growing evidence of the transformative potential of these treatments.\u003c\/p\u003e\n\n\u003ch2 id=\"idecel\"\u003eIdecabtagene Vicleucel (Ide-cel)\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eIdecabtagene vicleucel (Ide-cel)\u003c\/strong\u003e is an autologous (a patient's own) T-cell therapy genetically engineered with a \u003cstrong\u003elentiviral vector\u003c\/strong\u003e to express a chimeric antigen receptor (CAR) that targets BCMA on myeloma cells. The receptor includes a \u003cstrong\u003emurine (mouse-derived) extracellular single-chain variable fragment (scFv)\u003c\/strong\u003e specific for BCMA. When the anti-BCMA receptor binds to target cells, it triggers a signaling cascade through the \u003cstrong\u003eCD3ζ and 4-1BB costimulatory domains\u003c\/strong\u003e, leading to CAR-T cell activation, proliferation, and production of cytokines against BCMA-expressing cells.\u003c\/p\u003e\n\n\u003cp\u003eIn the pivotal \u003cstrong\u003eKarMMa-1 trial\u003c\/strong\u003e, \u003cstrong\u003e100 RRMM patients\u003c\/strong\u003e received one infusion of Ide-cel after lymphodepleting chemotherapy with cyclophosphamide and fludarabine. Results were impressive:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eORR of 72%\u003c\/strong\u003e (95% confidence interval: 62–81)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStringent complete response (sCR) rate of 28%\u003c\/strong\u003e (95% CI: 19–38)\u003c\/li\u003e\n  \u003cli\u003eAfter a median follow-up of \u003cstrong\u003e10.7 months\u003c\/strong\u003e, the median duration of response was \u003cstrong\u003e11 months\u003c\/strong\u003e (95% CI: 10.3–11.4) in responders with at least a partial response\u003c\/li\u003e\n  \u003cli\u003eFor patients who achieved stringent complete response, the median DOR was \u003cstrong\u003e19 months\u003c\/strong\u003e (95% CI: 11.4 months to not estimable)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn plain terms, nearly three-quarters of heavily pre-treated patients responded, and patients who achieved a complete response enjoyed a median duration of response of about a year and a half.\u003c\/p\u003e\n\n\u003ch2 id=\"ciltacel\"\u003eCiltacabtagene Autoleucel (Cilta-cel)\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eCiltacabtagene autoleucel (Cilta-cel)\u003c\/strong\u003e is a \u003cstrong\u003esecond-generation\u003c\/strong\u003e genetically engineered autologous CAR-T therapy that uses \u003cstrong\u003esingle-domain antibodies against two separate epitopes (binding sites) on the BCMA antigen\u003c\/strong\u003e. This \"dual targeting\" of BCMA is designed to enhance efficacy. Cilta-cel is the \u003cstrong\u003esixth CAR-T agent approved by the FDA\u003c\/strong\u003e for B-cell malignancies (following tisa-cel, axi-cel, brexu-cel, liso-cel, and ide-cel) and the \u003cstrong\u003esecond approved agent for multiple myeloma\u003c\/strong\u003e (after Ide-cel).\u003c\/p\u003e\n\n\u003cp\u003eThe phase 1 \u003cstrong\u003eLegend-2 trial in China\u003c\/strong\u003e (described in Zhao et al., 2018) was a single-arm, open-label, multicenter study that initially evaluated Cilta-cel in \u003cstrong\u003e57 RRMM patients\u003c\/strong\u003e. The results demonstrated that a single Cilta-cel infusion produced a prompt, significant, and persistent response while maintaining an acceptable safety profile in heavily pre-treated patients:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eORR of 88%\u003c\/strong\u003e, including \u003cstrong\u003e68% complete responses\u003c\/strong\u003e, \u003cstrong\u003e5% VGPR\u003c\/strong\u003e, and \u003cstrong\u003e14% partial responses\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e63% of patients achieved minimal residual disease (MRD) negativity\u003c\/strong\u003e at the 10⁻⁵ threshold (meaning fewer than 1 in 100,000 cancer cells remained)\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eMedian time to first response: 1 month\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003eAt a median follow-up of \u003cstrong\u003e8 months\u003c\/strong\u003e: median progression-free survival was \u003cstrong\u003e15 months\u003c\/strong\u003e and median DOR was \u003cstrong\u003e14 months\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBy \u003cstrong\u003e2 years of follow-up\u003c\/strong\u003e, the results improved further: \u003cstrong\u003eORR was 97.9%\u003c\/strong\u003e and \u003cstrong\u003e82.5% of patients achieved stringent complete response\u003c\/strong\u003e. This means that long-term follow-up showed that virtually all treated patients responded, and more than 8 in 10 achieved a stringent complete response.\u003c\/p\u003e\n\n\u003cp\u003eThe pivotal \u003cstrong\u003eCARTITUDE-1 trial\u003c\/strong\u003e confirmed these findings with an ORR of \u003cstrong\u003e97%\u003c\/strong\u003e (sCR 82.5%) and a median DOR of \u003cstrong\u003e14 months\u003c\/strong\u003e (see Table 3).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTable 3. Approved CAR-T with Trial Data\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIdecabtagene vicleucel (Ide-cel)\u003c\/strong\u003e (Pivotal trial: KarMMa-1): ORR 72% (28% sCR), median DOR 11 months. Notable toxicities: CRS ~84%, neurotoxicity ~28%, cytopenias.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCiltacabtagene autoleucel (Cilta-cel)\u003c\/strong\u003e (Pivotal trial: CARTITUDE-1): ORR 97% (sCR 82.5%), median DOR 14 months. Notable toxicities: CRS ~95%, neurotoxicity ~20%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"comparison\"\u003eCilta-cel vs. Ide-cel: Efficacy Versus Toxicity\u003c\/h2\u003e\n\n\u003cp\u003eA multicenter retrospective study directly compared safety outcomes and efficacy of Cilta-cel and Ide-cel in patients with RRMM who had been treated with \u003cstrong\u003eat least 4 prior lines of therapy\u003c\/strong\u003e. This head-to-head comparison provided crucial insights:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEfficacy comparison:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eORR:\u003c\/strong\u003e Ide-cel 79% vs. Cilta-cel \u003cstrong\u003e89%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBest complete response:\u003c\/strong\u003e Ide-cel 47% vs. Cilta-cel \u003cstrong\u003e70%\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProgression-free survival and overall survival:\u003c\/strong\u003e Both were \u003cstrong\u003esuperior with Cilta-cel\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSafety comparison:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePatients treated with Cilta-cel experienced a \u003cstrong\u003estatistically significant increase in grade ≥3 CRS\u003c\/strong\u003e compared to those treated with Ide-cel\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDelayed neurotoxicity\u003c\/strong\u003e was statistically significantly higher with Cilta-cel\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInfections\u003c\/strong\u003e were also statistically significantly higher in the Cilta-cel cohort\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors summarize the trade-off clearly: \u003cstrong\u003eCilta-cel offers greater efficacy, but at the expense of greater toxicity\u003c\/strong\u003e. The limitations of this comparison include its retrospective design and the inherent biases of real-world data. Nonetheless, this information is invaluable for patients and oncologists weighing the risks and benefits of each option.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe treatment landscape for relapsed\/refractory multiple myeloma has been revolutionized by bispecific antibodies and CAR-T cell therapies, offering unprecedented efficacy for heavily pre-treated patients. Several key takeaway points emerge from this review:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSequential therapy works.\u003c\/strong\u003e The successful use of Talquetamab as a bridge to CAR-T therapy—with 89% of patients able to proceed to CAR-T—demonstrates the power of combining different immunotherapy approaches. Targeting GPRC5D first, then BCMA with CAR-T, allows dual targeting and deeper responses.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAge should not be a barrier.\u003c\/strong\u003e The study of patients over 75 years old showed that older patients achieved a higher overall response rate (62% vs. 53%) than younger patients, with no grade 4 toxicity events. While infections were more common in older patients (25% vs. 10%), the overall safety profile supports using Teclistamab in this population.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOutpatient treatment is feasible.\u003c\/strong\u003e The retrospective outpatient Teclistamab study showed that most patients could complete step-up dosing with a 3-day interval, and CRS requiring hospitalization was manageable with a median hospital stay of just 2 days.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNewer agents are highly effective but with trade-offs.\u003c\/strong\u003e Cilta-cel shows superior efficacy to Ide-cel, but with higher rates of serious CRS, delayed neurotoxicity, and infections. These trade-offs require careful shared decision-making between patients and their oncology teams.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe recent expansion of approvals to earlier lines of therapy—Ide-cel now approved after two prior lines and Cilta-cel for lenalidomide-refractory patients after one prior line—reflects growing evidence that these treatments are most effective when used earlier in the disease course.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of This Review\u003c\/h2\u003e\n\n\u003cp\u003eIt is important for patients to understand the limitations of the evidence presented in this review:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThis is a \u003cstrong\u003ereview article\u003c\/strong\u003e, not a prospective clinical trial. It synthesizes data from multiple sources, including clinical trials and real-world retrospective studies.\u003c\/li\u003e\n  \u003cli\u003eSeveral key studies were \u003cstrong\u003eretrospective\u003c\/strong\u003e, meaning they looked back at patient records and may include selection bias or underreporting of adverse events (such as the lower-than-expected CRS rates in the outpatient Teclistamab study).\u003c\/li\u003e\n  \u003cli\u003eThe Talquetamab bridging study had a \u003cstrong\u003erelatively short median follow-up\u003c\/strong\u003e (7.5 months from first dose and 4.9 months following CAR-T), so long-term durability of responses remains unknown.\u003c\/li\u003e\n  \u003cli\u003eLonger-term follow-up data for \u003cstrong\u003eLinvoseltamab\u003c\/strong\u003e are still pending, so its full efficacy and safety profile has not yet been established.\u003c\/li\u003e\n  \u003cli\u003eThe comparative study of Cilta-cel vs. Ide-cel was retrospective, not a randomized controlled trial, so unmeasured differences between patient groups could have influenced the results.\u003c\/li\u003e\n  \u003cli\u003eThese therapies have significant toxicities, including cytokine release syndrome, neurotoxicity, infections, and secondary malignancies. Although most are manageable, they require treatment at specialized centers with experienced care teams.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss sequencing options with your specialist.\u003c\/strong\u003e If you are being evaluated for CAR-T therapy, ask whether a bispecific antibody such as Talquetamab could be used as a bridge to reduce disease burden before CAR-T infusion.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not assume you are \"too old\" for newer therapies.\u003c\/strong\u003e Evidence from the Teclistamab studies suggests that patients over 75 can benefit substantially, though they may require closer monitoring for infections.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about outpatient treatment options.\u003c\/strong\u003e If you are starting Teclistamab, ask whether outpatient step-up dosing is available at your center—this approach appears feasible and may allow you to spend less time in the hospital. If you have concerns about CRS side effects, remember that when they occur, they are typically manageable.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand the trade-off between efficacy and toxicity when choosing between CAR-T options.\u003c\/strong\u003e If your medical team offers a choice between Ide-cel and Cilta-cel, ask about your individual risk factors for CRS, neurotoxicity, and infections to make an informed decision.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePay attention to side effect monitoring.\u003c\/strong\u003e Taste changes, skin changes, weight loss (Talquetamab), infections, and cytopenias are common with these therapies. Report new symptoms early so your team can manage them proactively.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe current era represents a paradigm shift in the treatment of relapsed\/refractory multiple myeloma. With deepening and more durable responses, these combination immunotherapy approaches hold the potential to transform multiple myeloma from a uniformly fatal disease into one with significantly improved survival outcomes and quality of life.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat are bispecific antibodies and CAR-T cell therapy for multiple myeloma?\u003c\/h3\u003e\n\u003cp\u003eBoth are immunotherapies that use your immune system to fight myeloma. Bispecific antibodies are engineered proteins that connect your T cells to myeloma cells, triggering their destruction. CAR-T therapy collects your own T cells, genetically modifies them to recognize cancer, and infuses them back as a living drug. Both are used when standard treatments stop working.\u003c\/p\u003e\n\u003ch3\u003eHow effective is Talquetamab as a bridge to CAR-T therapy?\u003c\/h3\u003e\n\u003cp\u003eIn a retrospective study of 134 patients, 119 patients (89%) successfully completed Talquetamab bridging and proceeded to CAR-T cell therapy. Among those, 95% achieved an overall response, 71% achieved a very good partial response or better, and 52% achieved a complete or stringent complete response. This sequential approach allowed dual targeting of different myeloma markers.\u003c\/p\u003e\n\u003ch3\u003eCan Teclistamab be given in an outpatient setting?\u003c\/h3\u003e\n\u003cp\u003eYes, a retrospective study of 57 patients showed outpatient step-up dosing was feasible. About 54% completed dosing using a 3-day interval, and 31.6% developed cytokine release syndrome, all requiring hospital admission. The median CRS-related hospital stay was only 2 days. This offers a more convenient option without compromising safety.\u003c\/p\u003e\n\u003ch3\u003eShould age prevent older patients from receiving Teclistamab?\u003c\/h3\u003e\n\u003cp\u003eNo. A retrospective multicenter study compared patients over 75 with younger patients. Overall response rate was 62% in older patients versus 53% in younger patients. No grade 4 toxicity occurred in older patients. Infections were more common (25% vs 10%), but the authors recommend that age alone should not preclude Teclistamab treatment.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects does Talquetamab cause?\u003c\/h3\u003e\n\u003cp\u003eTalquetamab commonly causes cytokine release syndrome (78%), taste changes (60%), skin changes (70%), and weight loss (30%). These side effects are related to GPRC5D expression on hair follicles. Most are manageable with supportive care and monitoring. Always report new symptoms to your care team early.\u003c\/p\u003e\n\u003ch3\u003eWhat is the overall response rate for Elranatamab?\u003c\/h3\u003e\n\u003cp\u003eIn the phase 2 MagnetisMM-3 trial, Elranatamab achieved a confirmed overall response rate of 61.0%, with 35% complete responses. Many responses were durable, with 71.5% of responders maintaining response at 14.7 months. Notably, there were no grade 3 or 4 cytokine release syndrome events, which is reassuring for safety.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with relapsed\/refractory multiple myeloma seek a second opinion on treatment with bispecific antibodies versus CAR-T therapy?\u003c\/h3\u003e\n\u003cp\u003eSeek a second opinion when choosing between bispecific antibodies and CAR-T therapy, or when planning their sequence. Talquetamab successfully bridges to CAR-T, with 89% of patients going on to CAR-T. Teclistamab is effective in patients over 75, and outpatient step-up dosing is feasible. Cilta-cel has higher response rates than Ide-cel but greater toxicity. Because these options differ in efficacy, side effects, and convenience, a second opinion can clarify which approach fits your disease burden and risk profile. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Bispecific Antibodies and CAR-T cell Therapy in Multiple Myeloma\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Margaret Locke, Amanda Lee, and Maria J Nieto, Department of Cancer, Northwell Health Cancer Institute \u0026amp; Donald and Barbara Zucker School of Medicine at Hofstra, Lake Success, NY, USA\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Journal of Clinical Haematology, 2026; Volume 7, Issue 1, pages 13–18\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication Dates:\u003c\/strong\u003e Received November 10, 2025; Accepted January 27, 2026\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCitation:\u003c\/strong\u003e Locke M, Lee A, Nieto MJ. Bispecific Antibodies and CAR-T cell Therapy in Multiple Myeloma. J Clin Haematol. 2026;7(1):13–18.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e The research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflict of Interest:\u003c\/strong\u003e The authors declared no conflicts of interest.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. The original article is an open-access publication distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47471114977436,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/fr\/products\/bispecific-antibodies-and-car-t-cell-therapy-in-multiple-myeloma-a-patients-guide-to-new-immunotherapy-approaches","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}